Alanine Transaminase (ALT) levels (for Phase 1);Aspartate Transaminase (AST) levels (for Phase 1);Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 2);Creatine Phosphokinase (CPK) levels (for Phase 1);Incidence of solicited local Adverse events (AEs) at the injection site (for Phase 1);Incidence of solicited systemic AEs (for Phase 1);Incidence of unsolicited AEs (for Phase 1);Percentage of subjects who seroconverted (for Phase 2);Platelets levels (for Phase 1);Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 2);Red Blood Cell (RBC) levels (for Phase 1);SARS-CoV-2 neutralizing antibody titer (for Phase 2);White Blood Cell (WBC) levels (for Phase 1)

Alanine Transaminase (ALT) levels (for Phase 1);Aspartate Transaminase (AST) levels (for Phase 1);Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 2);Creatine Phosphokinase (CPK) levels (for Phase 1);Incidence of solicited local Adverse events (AEs) at the injection site (for Phase 1);Incidence of solicited systemic AEs (for Phase 1);Incidence of unsolicited AEs (for Phase 1);Percentage of subjects who seroconverted (for Phase 2);Platelets levels (for Phase 1);Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 2);Red Blood Cell (RBC) levels (for Phase 1);SARS-CoV-2 neutralizing antibody titer (for Phase 2);White Blood Cell (WBC) levels (for Phase 1)